Key facts
- This page summarizes Carlos A. Trujillo's Form 4 filing for PharmaCyte Biotech, Inc. (PMCB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Nov 2023, 17:01.
Carlos A. Trujillo - 20 Nov 2023 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)
- Reporting relationship
- Chief Financial Officer, Director
- Issuer ticker
- PMCB
- Reported as of
- 20 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2023, 17:01:45 UTC
- Prior SEC filing
- 03 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carlos A. Trujillo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carlos A. Trujillo filed Form 4 for PharmaCyte Biotech, Inc. (PMCB) on 22 Nov 2023.
Change
- Previous filing in this sequence was filed on 03 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMCB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +85,000
- Change %
- Price
- $0.000000
- Shares after
- 85,000
- Date
- 20 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,000
- Exercise price
- $2.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest 50% on November 20, 2023 and 50% on November 20, 2024.